Background: Female sex hormones are known to have immunomodulatory effects. Therefore,
INTRODUCTION
Multiple myeloma (MM) is a malignancy characterized by the accumulation of clonal plasma cells in the bone marrow, abnormal secretion of monoclonal protein and end organ damage (1) . Incidence rates are higher in men than in women (2) MM risk and reproductive factors, such as parity (3) (4) (5) (6) or use of postmenopausal hormone therapy (HT) (6) (7) (8) , but yielded inconsistent results as most studies were underpowered. We conducted a pooled analysis of case-control studies included in the International Multiple Myeloma Consortium (IMMC) to clarify the role of hormonal factors in the etiology of MM.
MATERIALS AND METHODS
We pooled individual-level questionnaire data from the seven IMMC case-control studies that collected information on reproductive factors among women (1,072 cases and 3,541 controls). These Enrollment period, age eligibility, study design, sample sizes, and participation rates within each study are summarized in Supplemental Table 1 . Parity was defined as number of live-births in NCI-Yale, iMAGE, and RCPI, and as number of children in all other studies.
Within each study, we computed odds ratios (ORs) with corresponding 95% confidence intervals (CI) using unconditional logistic regression, adjusting for age group (four categories), race (except for Epilymph, which did not collect these data), and study center (for multicentric studies: Epilymph and FHCRC 1980s). Random-effects models were used to calculate pooled estimates using the DerSimonian & Laird method. Heterogeneity between studies was assessed using the I 2 statistic and p-heterogeneity using the Mantel-Haenszel method. Analyses on parity and gravidity were restricted to women aged 45 or older, as they are likely to have completed their reproductive history. Analyses on HT were restricted to postmenopausal women, defined as women who reported cessation of their menstrual periods. Wald tests were utilized to assess heterogeneity between strata.
RESULTS
In this pooled analysis, we did not observe any statistically significant association between MM and age at menarche or at menopause, ever pregnant, number of pregnancies, ever parous, number of children, age at first birth, or cause of menopause ( Table 1) . The association between MM and ever use of hormonal contraceptives was not significant (OR=1.04, 95%CI=0.80-1.36; Table 1 ). Similarly, we saw no an Italian case-control study (8) , but these associations were not corroborated in two cohort studies (6,7).
However, conclusions in these studies have been limited by small sample sizes of women using HT.
Our study was based on a large dataset with individual-level information on reproductive factors and exogenous hormone use, yet we did not observe consistent patterns with these factors and MM risk.
We had the ability to control for a variety of potential confounders, including education, BMI and alcohol use. Ignoring these variables may have biased previous studies of HT and cancer, due to the potential for selection bias and a healthy user effect. We did not observe clear evidence of confounding by those variables in the present analysis, although residual confounding cannot be discarded in explaining some of our results, in particular for HT. Also, use of controls that may not be representative of the population from which the cases arose was an inherent limitation of some of the participating studies' design. In summary, our data do not support a significant role for reproductive factors or exogenous hormones in myelomagenesis.
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